Noval Remedies Private Limited - Company Profile

It is a chemicals private limited company based in Delhi, Delhi, India, established in 2020.
2020 Delhi, Delhi, India Active
Last Updated:
Access Report
About Noval Remedies Private Limited

Noval Remedies Private Limited, a active private limited company, was established on 10 June 2020 in Delhi, Delhi, India. Engaging in manufacturing within the chemicals sector, it holds CIN: U24290DL2020PTC364661. Registered under ROC Roc Delhi I. it is unlisted. It has an authorized capital of ₹0.10 M and a paid-up capital of ₹0.10 M.

Its leadership includes Seema Moolri (Director), Divya Kumar Jain (Director), Sahil Sapra (Director). It is based at 4378/4B 1St Floor Pooja Apartment Ansari Road Daryganj, Delhi, Delhi, 110002.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24290DL2020PTC364661

  • Registration Number

    364661

  • Incorporation Date

    10 June 2020

  • Authorized Capital

    ₹0.10 M

  • Paid-Up Capital

    ₹0.10 M

  • ROC Code

    Roc Delhi I

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 0.10 M
  • Paid Up Capital ₹ 0.10 M
  • Company Age 5 Year, 9 Months
Company report

Noval Remedies Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Noval Remedies Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Noval Remedies Private Limited?
Current Directors
Name Designation Appointment Date Status
Seema Moolri Director 10 Jun 2020 Current
Divya Kumar Jain Director 10 Jun 2020 Current
Sahil Sapra Director 10 Jun 2020 Current
Sunil Kapoor Director 10 Jun 2020 Current

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Noval Remedies.

Enhance accessibility to Noval Remedies's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.

Noval Remedies revenue growth over time
Noval Remedies profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
*******
*******
*******
*******
*******
Revenue from Operations
*******
*******
*******
*******
*******
*******
Total Assets
*******
*******
*******
*******
*******
*******
Profit or Loss
*******
*******
*******
*******
*******
*******
Net Worth
*******
*******
*******
*******
*******
*******
EBITDA
*******
*******
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Noval Remedies?

Unlock access to Noval Remedies's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

How Many Employees Work at Noval Remedies?

Noval Remedies has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Noval Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Noval Remedies's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Noval Remedies
Recent Activity within the Organization
  • Director Appointment

    Progress on Seema Moolri was appointed as a Director was appointed as a Director on 10 Jun 2020 & has been associated with this company since 5 years 9 months . was documented.

  • Director Appointment

    Divya Kumar Jain was appointed as a Director was appointed as a Director on 10 Jun 2020 & has been associated with this company since 5 years 9 months . was recorded as a recent event.

  • Director Appointment

    The activity Sahil Sapra was appointed as a Director was appointed as a Director on 10 Jun 2020 & has been associated with this company since 5 years 9 months . was completed.

  • Director Appointment

    Sunil Kapoor was appointed as a Director was appointed as a Director on 10 Jun 2020 & has been associated with this company since 5 years 9 months . was recorded as a recent event.

  • Company Incorporation

    Progress on Noval Remedies Private Limited was registered on 10 Jun 2020 with Roc Delhi I & aged 5 years 9 months as per MCA records. was documented.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Noval Remedies Private Limited?

The CIN of Noval Remedies Private Limited is U24290DL2020PTC364661.

Where is Noval Remedies Private Limited headquartered?

Noval Remedies Private Limited is headquartered at 4378/4B 1St Floor Pooja Apartment Ansari Road Daryganj, Delhi, Delhi, 110002.

When was Noval Remedies Private Limited incorporated?

Noval Remedies Private Limited was incorporated on 10 June 2020.

Who are the current directors of Noval Remedies Private Limited?

The current directors of Noval Remedies Private Limited are

What is the primary industry of Noval Remedies Private Limited?

The primary industry of Noval Remedies Private Limited is Chemicals.

Is Noval Remedies Private Limited a listed company?

Noval Remedies Private Limited is unlisted.

What is the capital structure of Noval Remedies Private Limited?

The authorized capital of Noval Remedies Private Limited is ₹0.10 M, and the paid-up capital is ₹0.10 M.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available